Subject Index

A

Abdominal constriction 187
Abstinence 7
Aquisition 287
Adrenaline 1
ADTN 195
Adult human males 123, 135
Aggression 59
Aggressive behavior, isolation-induced 75
Alcohol 123
l-Alpha-acetylmethadol 237
Amino acid turnover 111
d-Amphetamine 43, 71, 249
Androgen 75
Animal model of addiction 273
Anti-androgen 75
Apomorphine 169, 217, 249
Appetite 101
Appetitive learning 205
Artificial respiration 105
Assay 29
Audiogenic seizures 17
Auditory vigilance 213
Autoradiography 53

B

Barbital 93
Barbiturates 7
Behavior 71, 119
—, aggressive 75
—, genetics 49
—, gross 261
—, operant 21, 43
—, social 87
Behavioral pathology 59
Benzodiazepines 81, 101
Blood levels 29
—, platelets 183
Body weight 225
Brain 53
—, acetylcholine 97
—, acetylcholinesterase 97
—, lesions 71
—, NE and 5HT uptake inhibition 33
Butyrophenones 135

C

Caffeine 165
Cannabis 59
Carbachol 105
Catecholamine, excretion 1
Cats 101
Chemostimulation 105
Chlordiazepoxide 281
Chlorpromazine 205
Cigarettes 165
CNS Sensitivity 93
Coffee 165
Color-word conflict 1
Conditioning 273
Critical flicker frequency (CFF) 175
Cyproheptadine 271

D

Dimethyltryptamine 29
Discrete trials 205
Discrimination 205
—, drug state 153
—, performance 43
Discriminative stimulus 65
Dissociation 153
DMT 29
Dogs 7
Dopamine 21, 287
—, receptors 195
L-Dopa 249
Dose-effect curve 209
Dose-response 149, 165
Doxepin 183
Drug dependence 7, 165
—, induced parkinsonism 111
—, interaction 165, 187
—, learning dissociation 203
—, state change 43
—, state dependency 203
Dyskinesia 271
Dystonia 199

E

Electroencephalogram 17, 261, 267
Ergometrine 195
Erotic stimuli 123
Ethanol 157
—, narcosis 49
—, withdrawal 17
Etonitazine consumption 273
Evoked activity 119

F

Flicker 175
Flurazepam 81
Flutamide 75
Food intake 101
Frontal cortex 119
Fusion frequency 175

G

Generalization 153
D-Glucose $^{14}C(U)$ 111
Glutamic acid 111
Glutamine 111
Gonadotropins 135
Glycine 111

H

Haloperidol 21, 135, 169, 217, 249
Heart rate 105
Hexobarbital 93
Hippocampal theta activity 203
Human Subjects 1, 29, 81, 123, 135, 141, 165, 169, 175, 183, 199, 213, 271, 281
Humoral modulators 243
6-Hydroxydopamine 21, 195
Hypnotics-residual effects 213
Hypothalamus 105

I

Individual variation 213
Insomnia 81
Isopropranol 157
Instructional control 123
Intestinal motility 187
Intraperitoneal route 87
Intracisternal 49

L

Latencies 205
Length of addiction 273
Locomotor activity 49
—, spontaneous 243
—, stimulants 195
Locomotion 59
LSD 65

M

Macaca mulatta 71
Medial septal lesions 203
Mercury strain gauge 123
Mescaline 261, 267, 287
Metabolism 53
Methadone 209, 237
Methaqualone 7
Metoclopramide 169
Mice 17, 49, 75, 87, 187
Monkeys 53, 71, 119
Morphine 65, 149, 209, 237, 243
—, type physical dependence 225
Mouse-killing 59

N

Naloxone 243
Narcotic addiction 237
—, analgesics 65, 225
—, antagonist 65
—, blockade 273
Neurotransmitter balance 199
Nicotine 165
Nociception 261, 267
Noradrenaline 1
Norepinephrine 105, 287
Nucleus accumbens 195

O

Operant behavior 21, 43

P

Paid volunteers 281
Parachlorophenylalanine (pCPA) 287
Parkinson's disease 169
Pentobarbital 119, 203
Perception 175
Performance 287
Pharmacokinetics 199
Phenothiazines 111
—, reaction 271
Pigeons 157
Pilocarpine 59
Pimozide 21
Pirandamine 33
Pituitary hormones 135
Potential antidepressants 33
Prazepam 281
Prolactin 135
Prostaglandin E_1 187
Psychometrics 141
Psychomotor effects 281
Psychotomimetic 65
Psychotropic drugs 175

R

Rabbits, 261, 267
Rat brain 111
—, liver 111
Rats 21, 33, 43, 59, 65, 93, 97, 105, 111, 149, 153, 195, 203, 205, 209, 217, 225, 237, 243, 249, 273, 287
Rearing activity 59
Relapse 149
Reserpine 111
Rotation 249

S

Salsolinol 49
Schedule-controlled performance 157
Schizophrenia 29
Scopolamine 153, 249
Selected lines 49
Self-administration 209, 237
—, stimulation 21
Serine 111
Serotonin 183, 287,
—, antagonist 271
Sex differences 1
Sexual behavior 123
Shuttlebox avoidance 97
—, escape/avoidance 287
Sleep 81
—, awake cycle 237
Social behavior 87
Startle response 217
Strains 97
Stress 1
Subjective drug effects questionnaire 141
Sulpiride 169

T

Tandamine 33
Temperature 105
^{14}C-Tetrahydrocannabinol 53
Δ^9-Tetrahydrocannabinol 59, 87, 119, 141, 187
Times estimation 281
Tolerance 165
—, protracted 149
Triazolam 81

V

Vehicles 87
Venipuncture 1

Advice to Authors

The illustrations that will appear in your contribution will be shown to best advantage if you follow the brief set of instructions below. Please read carefully. Thank you.

The Publisher

Preparation of Line Drawings

Illustration copy should be prepared to fit the format of the printed page (print area) so that 1 : 1 reproduction is possible. Where reduction is necessary, please state the desired scale.

Drawings are to be twice the final size and executed in indelible black ink.

Important points to note: thickness of lines, size of inscriptions, size of measuring points, adequate spacing of shaded and dotted areas.

Words should be in upper and lower case characters, not CAPITALS.

The following are optimal sizes as they appear in the journal:
Capital letters and numbers: 2 mm
Lower-case letters: 1.6 mm.



1





2

samples 1 to 5 show the original size and reduction × 50%

3



4

ABCDEFGHIJKLMNOPQRSTUVWXYZ
aabcdefghijklmnopqrstuvwxyz
1234567890 1·5° III IV VIII IX ∞ % ≈
[(=-+x÷ !?:" ",)] (A) (B) (a) (b)

5

ABCDEFGHIJKLMNOPQRSTUVWXYZ
aabcdefghijklmnopqrstuvwxyz
1234567890 1·5° III IV VIII IX ∞ % ≈
[(=-+x÷ !?:" ",)] (A) (B) (a) (b)

Selection of Illustration Material for Halftones (photographs, micrographs, X-rays, instrument traces etc.).

Photographs should be sharp, well-contrasted glossy prints of the original negative, trimmed at right angles. Halftone illustrations should be prepared to fit the format of the printed page (print area) so that 1 : 1 reproduction is possible. But if reduction is absolutely necessary, please state the desired scale.

Mark or crop marginal portions which are not required (at right angles, please).

Please see that illustrations that are to appear together are mounted accordingly as plates and that they correspond. Also they should not exceed the print area of the page, including room for the legend.

With X-rays, please indicate the significant parts on the back of the copy, or on an overlay.

Inscriptions, marks and scale lines should preferably be drawn neatly in black ink in an appropriate size on the face of the illustrations. Inscriptions should be about 3 mm high. Where Letraset is used, please handle it carefully and protect the photographs with an overlay.



Clinical Pharmacology of Anti-Epileptic Drugs

International Symposium. Workshop on the Determination of Anti-Epileptic Drugs in Body Fluid II (WODADIBOF II)
Held in Bethel, Bielefeld, Germany, 24–25 May 1974

Editors: H. Schneider; D. Janz; C. Gardner-Thorpe; H. Meinardi; A.L. Sherwin

129 figures, 89 tables. X, 370 pages. 1975
Cloth DM 128,–; US $52.50
ISBN 3-540-06987-9
Prices are subject to change without notice

The proceedings of the Bethel meeting, apart from giving a record and naturally emphasizing the more recently introduced drugs, supplement the currently available reference books on the subject. The volume contributes to present knowledge about anti-epileptic drugs, gives the latest findings and theories on their pharmacokinetics, clinical pharmacology and evaluation as well as advances in analytical methods and presents controversial points of view discussed by experts in the field.

This manual is intended as a tool for both the clinician and the scientific worker in pharmacology, epileptology, neurology, pediatrics and neurophysiology as they relate to epileptic disorders. It serves not only to expand and augment knowledge about anti-epileptic drugs but should also improve the treatment of epilepsy patients by basing therapy to a greater extent than hitherto on pharmacokinetic principles.

Contents:

Pharmacokinetics.
Pharmacology of Anti-Epileptic Drugs.
Various Aspects (Varia).
Qualtity Control and Standardization.
Methodology of Determination.
Dictionary of Anti-Epileptic Drug Synonyms, Chemical Names and Nonproprietary Names.
Subject Index.

Springer-Verlag
Berlin
Heidelberg
New York

NEW FROM SPRINGER-VERLAG

Marihuana

Chemistry, Biochemistry, and Cellular Effects

Editor:
Gabriel G. Nahas
College of Physicians and Surgeons of Columbia University

Co-editors:
William D. M. Paton
University of Oxford

Juhana E. Idänpään-Heikkilä
Chief Medical Officer for Pharmacology, National Board of Health, Helsinki

1976. xix, 556p. 166 illus. 2 color plates, cloth $19.80
ISBN 0-387-07554-2

Recent scientific evidence indicates that marihuana has abnormal biochemical and cellular effects for the long-term user. This monograph reports the latest findings in the identification of specific chemicals contained in the cannabis plant and in the smoke resulting from its pyrolysis and produced in the body through biotransformation. For the first time, the inhibitory effect of cannabinoids on cell proliferation and DNA formation, *in vitro* and *in vivo*, and sperm formation is described. Micromethods of detection in body fluids, urine, plasma, and saliva are also included.

Contents

Marihuana Chemistry
- Detection and Identification of Cannabinoids and of Their Metabolites
- Kinetics and Biotransformation

Marihuana: Biochemical and Cellular Effects
- Effects on Isolated Cell Systems
- Interactions with Neurotransmitters
- Organic and Developmental Effects

Springer-Verlag
New York
Heidelberg
Berlin